Hormonal
Among women with Polycystic Ovary Syndrome (PCOS), the 'classic' phenotype (hyperandrogenism + oligoanovulation) is independently associated with insulin resistance, whereas the 'normoandrogenic' phenotype (oligoanovulation + polycystic ovaries) is not, after adjusting for body fat and age.
If you have PCOS, your specific symptoms matter for your metabolic health. Women with the 'classic' form (high male hormones + irregular periods) are at high risk for insulin resistance. However, women with the 'normoandrogenic' form (normal male hormones + irregular periods + cystic ovaries) have a much lower risk of insulin resistance, similar to healthy women. Ask your doctor to check your specific phenotype and tailor your metabolic screening (like glucose/insulin tests) accordingly, rather than assuming all PCOS patients are equally at risk.
Although none of the PCOS diagnostic features per se was associated with the impairment in insulin action, after adjustment for covariates, the classic phenotype and, to a lesser extent, the ovulatory phenotype were independently associated with insulin resistance, whereas the normoandrogenic phenotype was not.
Why this rating
High-quality observational study using the gold-standard hyperinsulinemic-euglycemic clamp technique on a large cohort (n=137), though it is cross-sectional.
Source
Divergences in Insulin Resistance Between the Different Phenotypes of the Polycystic Ovary Syndrome
Paolo Moghetti et al. · The Journal of Clinical Endocrinology & Metabolism · 2013
DOI 10.1210/jc.2012-3908
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →